- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07428564
En studie av VARIPULSE-kateter och TRUPULSE-generator med VARIPULSE PRO-programvara hos deltagare med PsAF (VP-EXTRA)
Workflow-studie av VARIPULSE™-katetern med TRUPULSE™-generatorn för behandling av persistent förmaksflimmer (PsAF) med den nya VARIPULSE™ Pro-mjukvaran
The main purpose of this study is to investigate the workflow of the clinical use of the pulsed field (PF) ablation system (VARIPULSE catheter and TRUPULSE generator) when used for cardiac ablation with the new VARIPULSE Pro software in participants with persistent atrial fibrillation (PsAF; irregular, rapid heart rhythm that lasts over 7 days and doesn't stop on its own)
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Aalst, Belgien, 9300
- AZORG campus Aalst Moorselbaan
-
Bruges, Belgien, 8000
- A.Z. Sint Jan
-
-
-
-
-
Aarhus N, Danmark, 8200
- Aarhus University Hospital
-
-
-
-
-
San Donato Milanese, Italien, 20097
- IRCCS Policlinico San Donato
-
-
-
-
-
Vilnius, Litauen, 08406
- Vilnius University Hospital Santaros Clinics
-
-
-
-
-
Bad Oeynhausen, Tyskland, 32545
- University Hospital of the Ruhr-University of Bochum
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion criteria:
- Diagnosed with symptomatic persistent atrial fibrillation (PsAF)
- Selected to undergo an ablation procedure for management of their arrhythmia by pulmonary vein isolation (PVI) +
- Failed at least one antiarrhythmic drug (AAD; class I to IV) as evidenced by recurrent symptomatic atrial fibrillation (AF), or intolerable or contraindicated to the AAD
- Age 18-75 years
- Willing and capable of providing consent
- Able and willing to comply with all pre-, post- and follow-up testing and requirements
Exclusion criteria:
- Continuous AF greater than (>) 12 months (1-Year) (Longstanding Persistent AF)
- Previous surgical or catheter ablation for atrial fibrillation
- Any cardiac surgery within the past 2 months (60 days prior to consent date) (includes percutaneous coronary intervention [PCI])
- Previous coronary artery bypass grafting (CABG) in conjunction with valvular surgery, cardiac surgery (for example, ventriculotomy, atriotomy) or valvular cardiac (surgical or percutaneous) procedure
- Any carotid stenting or endarterectomy
- Presence of left atrium (LA) thrombus
- Severe dilatation of the LA (left atrial diameter (LAD) > 50 millimeter [mm] antero-posterior diameter in case of transthoracic echocardiography [TTE])
- Severely compromised left ventricular ejection fraction (LVEF less than [<] 40%)
- Known significant pulmonary vein (PV) anomaly that in the opinion of the investigator would preclude enrollment in this study
- Prior diagnosis of pulmonary vein stenosis
- Pre-existing hemi diaphragmatic paralysis
- History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran)
- MI within the past 2 months (60 days prior to consent date)
- Documented thromboembolic event (including transient ischemic attack [TIA]) within the past 6 months (180 days prior to consent date)
- Rheumatic Heart Disease
- Uncontrolled heart failure or New York Heart Association (NYHA) function class III or IV
- Severe mitral regurgitation
- Anticipated cardiac transplantation, cardiac surgery, or other major surgery within the next 12 months
- Unstable angina pectoris within the past 6 months prior to consent date
- Acute illness or active systemic infection or sepsis
- Previously known AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause (for example, documented obstructive sleep apnea, acute alcohol toxicity, morbid obesity (Body Mass Index >40 kilogram per meter squared [kg/m^2]), renal insufficiency (with an estimated creatinine clearance < 30 mL/min/1.73 m^2)
- Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch, prosthetic valve or other abnormality that precludes catheter introduction or manipulation
- Presence of intramural thrombus, tumor or other abnormality that precludes vascular access, or manipulation of the catheter
- Presence of any other condition that precludes appropriate vascular access (such as Inferior Vena Cava [IVC] filter)
- Significant pulmonary disease, (for example, restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease [COPD]) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms
- Significant congenital anomaly or medical problems that in the opinion of the investigator would preclude enrollment in this study
- Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of childbearing age and plan on becoming pregnant during the course of the clinical investigation.
- Current enrollment in an investigational study evaluating another device, biologic, or drug
- Presenting contra-indications for the devices used in the study, as indicated in the respective instruction for use (IFU)
- Categorized as vulnerable population and requiring special treatment with respect to safeguards of well-being
- Life expectancy less than 12 months
- Contraindication for MRI such as use of contrast agents due to advanced renal disease, claustrophobia, implantable pacemakers, implantable cardioverter/defibrillators (ICDs),etc. (at PI discretion)
- Presence of iron-containing metal fragments in the body
- Unresolved pre-existing neurological deficit
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Pulsed Field Ablation: VARIPULSE Catheter with TRUPULSE Generator and VARIPULSE Pro Software
Participants undergoing cardiac ablation for management of treatment of symptomatic Persistent Atrial Fibrillation (PsAF) will undergo pulsed field ablation (PFA) with the VARIPULSE Catheter and the TRUPULSE Generator with the new VARIPULSE Pro software. |
Pulsed field ablation by VARIPULSE catheter with TRUPULSE generator along with VARIPULSE Pro software will be used. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Acute Procedural Success
Tidsram: Intraoperative
|
Acute procedural success, which is defined as electrical isolation of clinically relevant targeted PVs (confirmed by entrance block) after adenosine/isoproterenol challenge at the end of the index ablation procedure will be reported. |
Intraoperative
|
|
Pulmonary Vein Isolation (PVI) Durability
Tidsram: Up to 3 months post index ablation procedure
|
PVI durability is defined as sustained isolation of PVs that are targeted in the index ablation procedure, which is evidenced by the confirmation of isolation via the electro-anatomical mapping 90 days (+/- 14 days) post index ablation procedure. |
Up to 3 months post index ablation procedure
|
|
Pulsed Field (PF) Applications Time
Tidsram: Intraoperative
|
PF applications time will be reported. |
Intraoperative
|
|
Number of PF applications
Tidsram: Intraoperative
|
Number of PF applications will be reported. |
Intraoperative
|
|
Tissue Proximity Indication (TPI)
Tidsram: Intraoperative
|
TPI will be reported. |
Intraoperative
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Occurrence of Serious Adverse Device Effects (SADE) (Within Seven (7) days) of Index Ablation Procedure) Where the Investigational Devices were Used per Clinical Investigation Plan
Tidsram: Up to 7 days post index ablation procedure
|
A SADE is an adverse device effect that has resulted in any of the consequences characteristic of an serious adverse event (SAE). A SAE is any event that led to any of the following: Death, Serious deterioration in the health of a participant that resulted in any of the following: life-threatening illness or injury, permanent impairment of a body structure or a body function, in-patient hospitalization or prolongation of patient hospitalization, medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to body structure or a body function, chronic disease and fetal distress, fetal death or a congenital physical or mental impairment or birth defect. |
Up to 7 days post index ablation procedure
|
|
Occurrence of Unanticipated Serious Adverse Device Effects (USADEs)
Tidsram: Up to 3 months post index ablation procedure
|
An USADE is any SAE on health, safety, any life-threatening problem, or death caused by, or associated with a device, if that effect, problem, or death was not previously identified in nature, severity, outcome, or degree of incidence in the current investigational plan or risk analysis report, or any other unanticipated serious problem associated with a device that relates to rights, safety, or welfare of participants. |
Up to 3 months post index ablation procedure
|
|
Occurrence of SAEs
Tidsram: At 7 days, 8 to 30 days (peri-procedural) and up to 3 months post index ablation procedure
|
An SAE is any event that led to any of the following: Death, Serious deterioration in the health of a participant that resulted in any of the following: life-threatening illness or injury, permanent impairment of a body structure or a body function, in-patient hospitalization or prolongation of patient hospitalization, medical or surgical intervention to prevent ife-threatening illness or injury or permanent impairment to body structure or a body function, chronic disease and fetal distress, fetal death or a congenital physical or mental impairment or birth defect. |
At 7 days, 8 to 30 days (peri-procedural) and up to 3 months post index ablation procedure
|
|
Occurrence of Non-Serious Adverse Events (Non-SAEs)
Tidsram: Up to 3 months post index ablation procedure
|
An Adverse Event (AE) means any untoward medical occurrence, unintended disease or injury or any untoward clinical signs, including an abnormal laboratory finding, in participants, users or other persons, in the context of a clinical investigation, whether or not related to the investigational device. |
Up to 3 months post index ablation procedure
|
|
Occurrence of New Post-Ablation Asymptomatic and Symptomatic Cerebral Emboli Observed Post-Ablation as Determined by Magnetic Resonance Imaging (MRI) Evaluations
Tidsram: Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure
|
Occurrence of new post-ablation asymptomatic and symptomatic cerebral emboli will be evaluated using cerebral MRI performed post-ablation. |
Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure
|
|
Anatomical Location of New Post-Ablation Asymptomatic and Symptomatic Cerebral Emboli Observed Post-Ablation as Determined by MRI Evaluations
Tidsram: Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure
|
Anatomical location of new post-ablation asymptomatic and symptomatic cerebral emboli will be evaluated using cerebral MRI performed post-ablation. |
Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure
|
|
Size of New Post-Ablation Asymptomatic and Symptomatic Cerebral Emboli Observed Post-Ablation as Determined by Magnetic Resonance Imaging (MRI) Evaluations
Tidsram: Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure
|
Size of new post-ablation asymptomatic and symptomatic cerebral emboli will be evaluated using cerebral MRI performed post-ablation. |
Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure
|
|
Occurrence of New or Worsening Neurological Deficits
Tidsram: Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure
|
Occurrence of new or worsening neurological deficits will be assessed. |
Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure
|
|
Mini Mental State Examination (MMSE) Total Score
Tidsram: Baseline (within 72 hours prior to ablation), and post-ablation (72 hours after ablation procedure)
|
The MMSE is a, structured examination of cognitive function. It has a total score of 30 points (0-30), and any score equal to or lower than 26 points indicates cognitive impairment. |
Baseline (within 72 hours prior to ablation), and post-ablation (72 hours after ablation procedure)
|
|
National Institutes of Health Stroke Scale (NIHSS) Score
Tidsram: Baseline (within 72 hours pre ablation procedure), and post-ablation (72 hours after ablation procedure)
|
The NIHSS is a clinician-reported measure of neurological deficit with scores ranging from 0 to 42. No stroke symptoms (0), mild stroke (1-4), moderate stroke (5-15), moderate to severe stroke (16-20), and sever (21-42). |
Baseline (within 72 hours pre ablation procedure), and post-ablation (72 hours after ablation procedure)
|
|
Modified Rankin Scale (mRS) Scale Score
Tidsram: Baseline (within 72 hours pre ablation procedure), and post-ablation (72 hours after ablation procedure)
|
The mRS score is a validated score measuring neurologic outcomes after cardio-pulmonary resuscitation (CPR) where:
|
Baseline (within 72 hours pre ablation procedure), and post-ablation (72 hours after ablation procedure)
|
|
Occurrence of Severe Pulmonary Vein (PV) Stenosis
Tidsram: Up to 3 months post index ablation procedure
|
Occurrence of severe PV stenosis as determined by Computed Tomography (CT)/ Magnetic Resonance Angiogram (MRA) evaluations will be reported. |
Up to 3 months post index ablation procedure
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Biosense Webster, Inc. Clinical Trial, Biosense Webster, Inc.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- BWI202513
- BWI202513 (Annan identifierare: Biosense Webster, Inc.)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
The data sharing policy of Johnson & Johnson MedTech is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .